|Day Low/High||0.04 / 0.06|
|52 Wk Low/High||0.05 / 0.08|
These health care stocks are scheduled to report their quarterly earnings today.
Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript
Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript
Hovnanian and Blockbuster are among stocks under $5 with the most sell ratings from analysts.
Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.
Several stocks trading near $5 were moving on above-average volume during Monday's session.
Medivation's (MDVN) Alzheimer's drug, Dimebon, failed an important drug trial. Hard lessons were learned, as explained in this bonus Mailbag.
Drug maker may try to raise money as approvals of its kidney cancer drug stall out.
Several stocks trading near $5 were poised to move on above-average volume during Monday's session.
Can Poniard attract a partner for a chemo drug that causes less nerve toxicity but may not help patients live longer?
Several stocks trading near $5 were moving on above-average volume during Friday's session.
Biotech columnist Adam Feuerstein rolls out the year's first Mailbag, answering questions about Novelos and other stocks.
Several stocks trading under $5 were moving on above-average volume during Monday's session.
Poniard faces a cash-crunch situation after a failed drug test last week.
Several stocks trading under $5 were poised to move on above-average volume during Wednesday's session.
Poniard recovers part of Monday losses on data for picoplatin in colon cancer, and safety info
Poniard Pharma drops more than 70 percent after lung cancer drug fails in late stage trial
Risky late-game call puts Poniard in a deep financial hole.
Is it the drug or the gel that worked best in a phase II study?
'Retention' bonus awarded to CEO Jim Bianco, his management team and directors.
Poniard Pharma says picoplatin did not improve survival in late stage study; shares tumble
Lung cancer drug picoplatin doesn't prolong survival in phase III study.
Readers chime in on Poniard Pharmaceuticals, Chelsea Therapeutics, AMAG, Cel-Sci and Dendreon.
Poniard Pharmaceuticals shares rise as BMO Capital Markets analyst initiates with 'Outperform'
Another quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.